Viking Q4 net loss $0.26/shr; cash $155M; NASH study data expected Q2 2023

Viking Therapeutics, Inc.

2022-FY EPS reported -$0.90

Net loss $19.6M ($0.26/shr) for Q4 2022 vs $12.4M ($0.16/shr) in Q4 2021; R&D expense rose to $16.2M.
Full-year 2022 net loss $68.9M ($0.90/shr) vs $55.0M ($0.71/shr) in 2021; cash $155M (down from $202M).
Enrollment completed for Phase 2b VOYAGE study of VK2809 in NASH/fibrosis; topline data expected Q2 2023.
Phase 1 trial of dual GLP-1/GIP agonist VK2735 ongoing; initial data expected Q1 2023.
Phase 1b study of VK0214 in X-ALD enrolling; data expected H2 2023; cash runway beyond key milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Viking Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2022.

Period: fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 8, 2023, we issued a press release reporting our financial results for the fourth quarter and year ended December 31, 2022 and providing a corporate update.

View on SEC.gov

Browse all earnings releases →

Viking Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-23-001611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.